Navigation Links
Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
Date:4/18/2008

RADNOR, Pa., April 18 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP:

Notice is hereby given that a class action lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of all purchasers of securities of Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) ("Vertex" or the "Company") from June 12, 2007 through November 2, 2007, inclusive (the "Class Period").

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Schiffrin Barroway Topaz & Kessler, LLP (Darren J. Check, Esq. or Richard A. Maniskas, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@sbtklaw.com.

The Complaint charges Vertex and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Vertex is a biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. More specifically, the Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them: (1) that its new hepatitis C drug, telaprevir's, (or VX-950) results rivaled the findings on a similar Vertex drug; (2) that patients taking VX-950 only experienced a 6% advantage as compared to 16% in the previous study; and (3) that, as a result of the foregoing, the Company's statements about its financial well-being and future business prospects were lacking in any reasonable basis when made.

On November 2, 2007, the Company shocked investors when it disclosed less than stellar results from a phase of testing (PROVE 2) on telaprevir. The results came as a surprise to investors, since the Company failed to indicate the findings of PROVE 2 during the Class Period, when the results became known. The Company had touted the results of telaprevir in PROVE 1, which showed patient improvement at 16% as compared to the control group. However, patients in PROVE 2 displayed results that were only 6% more favorable than those of the control group, which cast serious doubt on the utility of the drug.

Upon the release of this news, the Company's shares immediately declined $2.74 per share, or 8.66 percent, to close on November 2, 2007 at $28.90 per share, on unusually heavy trading volume. As the news spread over the weekend, the stock declined even further, falling $4.82, or 16.68 percent, to close on November 5, 2007 at $24.08.

Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Schiffrin Barroway Topaz & Kessler which prosecutes class actions in both state and federal courts throughout the country. Schiffrin Barroway Topaz & Kessler is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.

For more information about Schiffrin Barroway Topaz & Kessler or to sign up to participate in this action online, please visit http://www.sbtklaw.com

If you are a member of the class described above, you may, not later than May 12, 2008, move the Court to serve as lead plaintiff of the class, if you so choose. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

CONTACT: Schiffrin Barroway Topaz & Kessler, LLP

Darren J. Check, Esq.

Richard A. Maniskas, Esq.

280 King of Prussia Road

Radnor, PA 19087

1-888-299-7706 (toll free) or 1-610-667-7706

Or by e-mail at info@sbtklaw.com


'/>"/>
SOURCE Schiffrin Barroway Topaz & Kessler, LLP
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Immtech Announces Posting of Annual Shareholders Meeting Presentation
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
4. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
5. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
6. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
7. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
8. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
11. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
Breaking Medicine Technology:
(Date:2/12/2016)... Appleton, Wis. (PRWEB) , ... February 12, 2016 ... ... its second Lean Leadership Series at Zuckerberg San Francisco General Hospital on April ... to practice new behaviors and create new habits. The workshops cover a broad ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Fisher House Foundation ... Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns ... the VA Southern Nevada Healthcare System. This will be the first Fisher House ...
(Date:2/12/2016)... ... 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, PhD ... . The list consists of physicians establishing, leading and partnering with ambulatory surgery centers ... An Ambulatory Surgery Center, also known as an ASC, is a modern health care ...
(Date:2/12/2016)... ... 12, 2016 , ... Donor Network West, the organ procurement organization that heals ... with San Ramon Regional Medical Center. Under the collaboration, the first of its kind, ... accommodate a more certain time frame for donor families for the recovery of organs. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... surrounding communities by continuing it’s commitment to act as Agents of Change in ... works closely with area homeless families to fulfill immediate needs and help them ...
Breaking Medicine News(10 mins):